Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 aPriori aPriori +195.44%
#4 Bedrock Bedrock +78.59%
#5 Cysic Cysic +52.73%
#6 Prom Prom +41.94%
#7 Playnance Playnance +35.03%
#8 Bitway Bitway +27.63%
#9 Nillion Nillion +23.82%
#10 COTI COTI +23.81%
Coin of the day
Wrapped One Wrapped One
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Regnum Corp. Regnum Corp.

Regnum Corp.

RGMP
Clasificación en acciones #42305
Regnum Corp. is dedicated to advancing and marketing therapeutic agents... Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$2.30K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Regnum Corp. (RGMP)

Categoría

Healthcare
Ganancias de Regnum Corp. (RGMP)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Regnum Corp., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Regnum Corp. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR